BAFNA PHARMACEUTICALS LTD. - 532989 - Discrepancy In Corporate Announcement (Board Meeting Notice)
We acknowledge the receipt of email dated 07th Feb 2020 regarding discrepancies in Corporate Announcement. Discrepancy: Unsigned Pdf File is submitted Our Reply: By inadvertence the letter was not signed. Signed letter is attached here with. Please take it on record. Bafna Pharmaceuticals Ltd - 532989 - Board Meeting Intimation for Quarterly Result
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2020 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 13th February 2020 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the quarter ended 31st December 2019 and any other business with the permission of the Chair. Bafna Pharmaceuticals Ltd - 532989 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer Bafna Pharmaceuticals Ltd - 532989 - Shareholding for the Period Ended December 31, 2019
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here Bafna Pharmaceuticals Ltd - 532989 - Sub.:- Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Details Of Related Party Transactions
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, We hereby submit related party transactions as at 30th September 2019. Bafna Pharmaceuticals Ltd - 532989 - Sub.:- Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Details Of Related Party Transactions
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, We hereby submit related party transactions as at 30th September 2019. BAFNA PHARMACEUTICALS LTD. - 532989 - Result For The Quarter And Half Year Ending 30Th Sep 2019
We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the quarter / half year ending 30th September 2019. Please find attached the un-audited financial results for quarter / half year ending 30th September 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. The meeting commenced at 3.30 P.M. and concluded at 5.45 P.M. Bafna Pharmaceuticals Ltd - 532989 - Outcome Of The Board Meeting Held On 13Th November 2019
We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the quarter / half year ending 30th September 2019. Please find attached the un-audited financial results for quarter / half year ending 30th September 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. The meeting commenced at 3.30 P.M. and concluded at 5.45 P.M. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Inter-Alia Consider And Approve The Un-Audited Financial Results For The Quarter & Six Months Ending 30Th Sep 2019 And Other Business Matters
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, 13th November 2019 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the quarter and six months ended 30th Sep 2019 and any other business with the permission of the Chair BAFNA PHARMACEUTICALS LTD. - 532989 - Sub: Certificate From Practicing Company Secretary For The Half Year Ended 30Th September 2019 Ref: Regulation 40(9) Of The SEBI (LODR) Regulations, 2015
Please find attached Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September 2019. Request you to take the same on record.